NatureCellLtd Past Earnings Performance
Past criteria checks 0/6
NatureCellLtd's earnings have been declining at an average annual rate of -7.8%, while the Biotechs industry saw earnings growing at 14.4% annually. Revenues have been growing at an average rate of 2.2% per year.
Key information
-7.8%
Earnings growth rate
-1.1%
EPS growth rate
Biotechs Industry Growth | 11.7% |
Revenue growth rate | 2.2% |
Return on equity | -13.9% |
Net Margin | -37.8% |
Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Revenue & Expenses Breakdown
How NatureCellLtd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Mar 24 | 22,744 | -8,596 | 15,490 | 2,071 |
31 Dec 23 | 19,351 | -11,438 | 14,999 | 2,221 |
30 Sep 23 | 21,827 | -1,991 | 10,722 | 1,920 |
30 Jun 23 | 23,198 | -4,616 | 12,581 | 1,829 |
31 Mar 23 | 22,247 | -7,973 | 13,844 | 1,395 |
31 Dec 22 | 21,252 | -8,316 | 13,435 | 1,577 |
31 Dec 21 | 20,354 | -30,014 | 15,003 | 1,473 |
30 Sep 13 | 27,876 | -4,155 | 2,625 | 0 |
Quality Earnings: A007390 is currently unprofitable.
Growing Profit Margin: A007390 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if A007390's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare A007390's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A007390 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (13.4%).
Return on Equity
High ROE: A007390 has a negative Return on Equity (-13.87%), as it is currently unprofitable.